Early-stage eye heath technology company TearClear Corp. has raised $4.5 million through its Series A finnacing, which will be used to fund advanced development of its delivery system for preservative-free ophthalmic drugs.
TearClear's filter technology is reportedly the firrst and only system to assure the safe delivery of a preservative-free drop from preserved, multi-dose products. The chemical filter reportedly removes benzalkonium chloride (BAK) at the point of instillation, allowing multi-dose product preservation until the moment of application. According to TearClear, BAK is the most common preservative used in multi-dose topical ophthalmic drugs for the treatment of glaucoma, over-the-counter (OTC) dry-eye, and allergic conjunctivitis.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.